New Delhi, June 21: Hetero Group of companies company has reportedly received the manufacturing and marketing approval for Remdesivir from the Drug Controller General of India for the treatment of COVID-19.
The company's generic version of Remdesivir will be marketed under the brand name 'Covifor' in India.
The drug has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalised with severe symptoms of the disease.
If get successful, in the light of increasing COVID-19 cases in India, the approval of 'Covifor' (remdesivir) can prove to be a game-changer given its positive clinical outcomes.
Hetero Group of Companies Chairman said that the company is prepared for ensuring enough stock to cater to the present needs & the drug will be available in 100 mg vial (injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner.
|